WhatPeptide

BPC-157

A pentadecapeptide derived from human gastric juice that has demonstrated tissue-protective and regenerative properties across multiple animal models.

Animal studies only FDA Category 2 Healing & Recovery

Written by WhatPeptide Editorial Team · Last updated 2026-03-17

FDA Category 2 — compounding availability may be limited.

Half-life

Estimated <30 min systemic; stable >24h in gastric juice

Dosage range

200-500 mcg daily (research/compounding context)

Administration

Subcutaneous injection

Research level

Animal only

How BPC-157 works

BPC-157 appears to modulate nitric oxide signaling and growth-factor pathways including VEGF and EGF. Preclinical work suggests effects on angiogenesis, tendon-to-bone healing, and epithelial repair. Human interventional data remains limited and mostly uncontrolled.

Also known as: Body Protection Compound 157, PL 14736

Research relevance

Injury Rehab
Moderate relevance 65
Recovery & Healing
Moderate relevance 60
Gut Health
Moderate relevance 60
Hair & Skin
Some relevance 45
Anti-Aging & Longevity
Some relevance 35
Immune Support
Some relevance 35
Muscle Growth
Some relevance 20
Sleep & Relaxation
Some relevance 20
Cognition & Focus
Some relevance 20

Side effects & safety

Injection-site irritation Nausea Headache

Contraindications

Pregnancy/breastfeeding
Active malignancy without physician oversight

Consult a healthcare provider before use if any of these apply to you.

Key studies

FAQ

What is BPC-157? +
A pentadecapeptide derived from human gastric juice that has demonstrated tissue-protective and regenerative properties across multiple animal models. Its mechanism of action is based primarily on animal and in-vitro studies.
What is BPC-157 researched for? +
BPC-157 has the strongest research relevance for Injury Rehab, Recovery & Healing, Gut Health. Evidence is based primarily on animal and in-vitro studies.
What are the side effects of BPC-157? +
Reported side effects include Injection-site irritation, Nausea, Headache. Key contraindications: Pregnancy/breastfeeding; Active malignancy without physician oversight.
Is BPC-157 FDA approved? +
BPC-157 is classified as FDA Category 2, meaning compounding availability may be limited.
How is BPC-157 administered? +
BPC-157 is typically administered via subcutaneous route. Researched dosage range: 200-500 mcg daily (research/compounding context). Half-life: Estimated <30 min systemic; stable >24h in gastric juice.

Explore similar peptides

ARA-290

Preliminary evidence

Healing & Recovery

ARA-290 is a non-hematopoietic erythropoietin-derived peptide engineered to activate the innate repair receptor without stimulating red blood cell production, studied for neuropathic pain and tissue repair. Clinical trials have explored its utility in sarcoidosis-related nerve damage and diabetic neuropathy.

TB-500

Animal studies only

Healing & Recovery

A synthetic fragment associated with thymosin beta-4 signaling that is studied for migration, remodeling, and tissue repair in preclinical injury models.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

KPV

Preliminary evidence

Anti-Inflammatory

A short melanocortin-derived tripeptide studied for anti-inflammatory signaling in gut and skin models. Placed on FDA Category 2 list (September 29, 2023).